H.C. Wainwright Upgrades NovoCure Ltd. (NVCR) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Novocure (NVCR) Announces FDA Approval of Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer
October 15, 2024 4:44 PM EDTNovocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors or docetaxel, for the treatment of adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen.
Novocure is committed to extending survival in some of the most aggressive and difficult to treat cancers. The approval of Optune Lua brings a new and urgently needed option for people with metastatic NSCLC who have progressed while on or after platinum-based chemotherapy, said Asaf... More
After-hours movers: United Airlines, Interactive Brokers, J.B. Hunt and more
October 15, 2024 4:36 PM EDTAfter-Hours Stock Movers:
United Airlines (NASDAQ: UAL) rose 0.5% after it reported third quarter results that topped consensus estimates and approved a $1.5 billion buyback program, its first since 2020. Management noted that revenue trends improved as the industry reached... More
Novocure (NVCR): FDA Approves Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer
October 15, 2024 4:09 PM EDTNovocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors or docetaxel, for the treatment of adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen.
Novocure is committed to extending survival in some of the most aggressive and difficult to treat cancers. The approval of Optune Lua brings a new and urgently needed option for... More
